Ubidecarenone (CED0001307)

Ubidecarenone belongs to the quinone and hydroquinone lipids, a subclass of prenol lipids within the organic compounds. With an average molecular weight of 863.34 g/mol, Ubidecarenone is a heavy molecule with the formula C59H90O4. Biologically, it functions as an antioxidant (PMC10967835, PMC11722770, PMC12261812, PMC12279893, PMC12383105), a cofactor (PMC12835470), and an anti-inflammatory agent (PMC7070237). It is used industrially as a pharmaceutical (PMC10967835, PMC11722770, PMC12261812, PMC12279893, PMC12383105). Its recorded protein targets include the mitochondrial succinate dehydrogenase [ubiquinone] flavoprotein subunit (SDHA) and the mitochondrial NADH dehydrogenase [ubiquinone] flavoprotein 3 (NDUFV3). The compound is found in cardiac preparations, as well as in food, food processing and cookware, including the preparation of malt, vinegar, wine or sparkling wine. It is also present in household cleaning and consumer products, such as soap dispensers, tobacco product cases and non electric simulated smoking devices, and electrical and electronic equipment, including antennas and electric hearing aids. Recorded exposure routes include oral, topical, and cutaneous. Ubidecarenone is used as a treatment for obesity (PMC13359728), colorectal cancer (PMC12021792), amyotrophic lateral sclerosis (PMC7070237), multiple sclerosis (PMC7070237), infertility (PMC10388648), and male infertility (PMC9005387). It has therapeutic effects on glioblastoma (PMC12466395), infertility (PMC9476395), obesity (PMC11852089), inflammation (PMC11852089), depression (PMC11506420), fatigue (PMC11506420), anxiety (PMC7070237), nausea (PMC7070237), ischemia (PMC3431881), and pain (PMC9556195). Additionally, it is associated with an increase in lung cancer (PMC9657286) and is decreased in the blood of individuals with periodontal disease (PMC4665427).